BOSTON (PRWEB) November 13, 2019
David J. Dykeman, patent attorney and co-chair of Greenberg Traurig, LLP’s global Life Sciences & Medical Technology Group and Boston Intellectual Property & Technology (IP) Group, will present at the American Conference Institute’s (ACI) 3rd Annual Summit on Life Sciences IP Due Diligence, Nov. 14-15, 2019 in Boston, MA.
From 10:45 a.m. – 12:00 p.m. on Nov. 14, Dykeman will moderate the panel, “Avoiding Missteps During the Chain of Title Review: Understanding Ownership Rules,” which will address patent ownership questions related to the valuation of proprietary life sciences technology. Specific topics include:
- Who is the true owner of the patents?
- Have the patents been maintained in force and the patent applications in good standing?
- Have any prior investors or creditors encumbered the IP by imposing liens?
- Has there been a valid and inclusive assignment of patents to the licensor?
Panelists include: Jeffrey N. Myers, Vice President & Assistant General Counsel, Pfizer Inc.; Adam Strauss, Chief Intellectual Property Counsel, Stryker; Marina Volin, VP, Head of Legal and IP, Kintai Therapeutics, Inc.; and Jen Sieczkiewicz Zarutskie, VP, Chief Intellectual Property Counsel, Wave Life Sciences.
Dykeman has over 22 years of experience in patents, IP, and licensing, and focuses his practice on securing strategic worldwide IP protection and related business strategy for high-tech clients, with particular experience in life sciences, medical devices, biotechnology, and healthcare IT. He is the founding co-chair of the American Bar Association’s (ABA) Medical Devices Committee and served on the Editorial Advisory Board of Medical Device + Diagnostic Industry (MD+DI) magazine. An accomplished author and a speaker on medical devices and life sciences IP, Dykeman was honored as a “Life Science Star” by LMG Life Sciences, and was named one of the Top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) magazine.
ACI’s 3rd Annual Summit on Life Sciences IP Due Diligence provides a forum for key industry stakeholders to master how to cultivate, navigate, and apply the results of an effective and profitable due diligence analysis.
About Greenberg Traurig’s Life Sciences & Medical Technology Group: Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from start-ups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.
About Greenberg Traurig: Greenberg Traurig, LLP (GT) has approximately 2100 attorneys in 41 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law